Welcome to our dedicated page for Medexus Pharmace news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmace stock.
Medexus Pharms Inc (MEDXF), referred to in its disclosures as Medexus Pharmaceuticals, generates a steady flow of news related to its specialty pharmaceutical business in North America. Investors following MEDXF news can see updates on hematology and hematology-oncology products, as well as allergy, dermatology, and rheumatology therapies that form the company’s core portfolio.
Many Medexus news releases focus on GRAFAPEX (treosulfan) for Injection, an alkylating agent used as part of a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome. The company reports on FDA approval, Orphan Drug Designation, US commercial launch timing, and key reimbursement milestones such as CMS New Technology Add-On Payment (NTAP) approval, transitional pass-through status, and assignment of a permanent HCPCS Level II "J code". These items provide insight into how Medexus is building its hematology-oncology franchise in the United States.
MEDXF news also covers quarterly and annual financial results, including net revenue, net income, Adjusted EBITDA, and product-level performance for GRAFAPEX, Trecondyv, IXINITY, Rupall, Rasuvo, Metoject, and Gleolan. The company uses these releases to discuss unit demand trends, the impact of generic competition on products such as Rupall, and portfolio dynamics across the United States and Canada.
Additional news topics include financing and capital allocation decisions, such as new senior secured credit facilities with National Bank of Canada, repayment of prior credit agreements, and the launch or renewal of a normal course issuer bid (NCIB) for Medexus common shares on the Toronto Stock Exchange. Governance-related items, including annual meetings of shareholders, director elections, and auditor appointments, are also reported.
For anyone tracking MEDXF, this news stream offers detailed information on product launches, regulatory and reimbursement milestones, financial performance, credit arrangements, and share repurchase activity. Bookmarking the Medexus news feed on Stock Titan can help investors and researchers follow how the company’s North American specialty pharmaceutical platform evolves over time.
Medexus (OTCQX: MEDXF) reported fiscal Q3 2026 results and a business update for the quarter ended December 31, 2025.
Key points: Net revenue was $25.3M (Q3) and $74.7M (nine months). GRAFAPEX product-level revenue was $2.0M (Q3) and $8.2M (nine months) versus $8.5M of launch investment year-to-date. Adjusted EBITDA was $4.5M (Q3). Available liquidity: $15.0M.
Medexus (OTCQX: MEDXF) will host a conference call at 8:00 AM ET on Thursday, February 12, 2026 to discuss results for its third fiscal quarter ended December 31, 2025. The company expects to file its financial statements and MD&A after markets close on February 11, 2026.
A live webcast will be available on the Medexus Investors site with dial-in access for Canadian/U.S. and international callers. A telephone replay and archived webcast will be available through specified dates, with the webcast replay available until February 12, 2027.
Medexus (OTCQX: MEDXF / TSX: MDP) announced a normal course issuer bid (NCIB) accepted by the Toronto Stock Exchange, allowing purchases of up to 2,983,650 common shares, approximately 10% of the public float. As of November 12, 2025 there were 32,420,060 shares outstanding and a public float of 29,836,506. Purchases may begin on November 24, 2025 and run through November 23, 2026, will be funded from the company's general funds, executed on the TSX or alternative Canadian trading systems, and any shares purchased will be cancelled. The six‑month ADTV to October 31, 2025 was 40,066, limiting daily purchases to 10,016 shares under TSX rules, excluding block purchase exceptions.
Medexus (OTCQX: MEDXF) entered a new senior secured credit agreement with National Bank of Canada providing a US$21.0 million term loan and a US$5.0 million revolving loan, plus a US$10.0 million delayed draw feature and a US$15.0 million uncommitted accordion. The facilities mature on November 17, 2029. Medexus used net proceeds to repay existing senior secured facilities due March 2026. Borrowings bear adjusted term SOFR (or other base rate) plus a quarterly margin tied to consolidated net leverage; the initial weighted average interest rate is 6.74% versus the prior 6.95%. Medexus also intends to seek TSX approval for an NCIB to buy up to 10% of its public float over 12 months.
Medexus (OTCQX: MEDXF) reported fiscal Q2 2026 results for the period ended September 30, 2025, driven by early commercial traction for GRAFAPEX (treosulfan). Net revenue was $24.7M for the quarter and $49.4M year-to-date, down 6.1% and 7.8% YoY respectively. Medexus recorded product-level GRAFAPEX net revenue of $3.1M (Q2) and $6.2M (YTD) against ~$3.0M and $6.0M of launch investments. Adjusted EBITDA was $4.4M (Q2) and $7.8M (YTD). Available liquidity was $9.4M at Sept 30, 2025, after $16.6M principal repayments since March 31, 2025.
Medexus Pharmaceuticals (OTCQX: MEDXF) will hold a conference call at 8:00 AM ET on Thursday, November 13, 2025 to discuss results for the second fiscal quarter ended September 30, 2025. The company expects to file its financial statements and MD&A after markets close on November 12, 2025.
Live dial-in numbers are provided for Canadian/U.S. and international callers with Access Code 988000. A live webcast will be available on the Investors section of Medexus's website and a replay will be available by phone and online through Friday, November 13, 2026.
Medexus Pharmaceuticals (OTCQX:MEDXF) successfully conducted its virtual annual shareholders meeting, where all proposed directors were elected for the upcoming term. The shareholders demonstrated strong support for the board nominees, with approval ratings ranging from 92.19% to 96.45%.
Additionally, shareholders overwhelmingly approved the appointment of PricewaterhouseCoopers LLP as the company's auditors with 99.51% of votes in favor. The voting results will be filed with Canadian securities regulatory authorities.
Medexus Pharmaceuticals (OTCQX:MEDXF) reported fiscal Q1 2026 results, featuring $24.6 million in net revenue and $0.5 million in net income. The quarter highlighted the successful launch of GRAFAPEX, generating $3.0 million in product-level revenue. The company achieved $3.4 million in Adjusted EBITDA and $3.9 million in operating cash flow.
GRAFAPEX's launch shows promising momentum with 9 large commercial payers covering approximately 48 million patient lives, and 36 transplant centers representing 24% of total allo-HSCT procedures in the US already ordering the product. The company expects GRAFAPEX to be cash flow accretive by fiscal Q3 2026 and projects annual product-level revenue to exceed $100 million within five years.
The company reduced its total debt by $15.5 million to $22.0 million as of June 30, 2025, while maintaining $9.3 million in available liquidity.
Medexus Pharmaceuticals (OTCQX:MEDXF) has scheduled its first fiscal quarter 2026 earnings conference call for August 13, 2025, at 8:00 am Eastern Time. The company will release its financial results and MD&A for the quarter ended June 30, 2025, after market close on August 12, 2025.
Additionally, Medexus management will participate in two upcoming investor conferences: Cannacord Genuity's 45th Annual Growth Conference in Boston (August 12-14, 2025) and the LD Micro Main Event in San Diego (October 19-21, 2025).
Medexus Pharmaceuticals (OTCQX: MEDXF) has secured CMS approval for New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX (treosulfan) for Injection in fiscal year 2026. Starting October 1, 2025, eligible procedures will receive up to $21,411 in additional reimbursement through the NTAP program.
The approval marks a significant milestone, as GRAFAPEX was one of only five approvals out of 13 applications under the traditional pathway. Since its US commercial launch in February 2025, GRAFAPEX has gained positive formulary inclusion from 9 large commercial payers covering approximately 48 million patient lives, and 14 healthcare institutions. Additionally, 37 transplant centers have ordered GRAFAPEX, demonstrating strong initial institutional uptake.